GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zosano Pharma Corp (OTCPK:ZSANQ) » Definitions » Piotroski F-Score

Zosano Pharma (Zosano Pharma) Piotroski F-Score : 0 (As of Apr. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zosano Pharma Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zosano Pharma has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Zosano Pharma's Piotroski F-Score or its related term are showing as below:


Zosano Pharma Piotroski F-Score Historical Data

The historical data trend for Zosano Pharma's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zosano Pharma Piotroski F-Score Chart

Zosano Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 2.00 2.00 5.00 4.00

Zosano Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 4.00 4.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar22) TTM:Last Year (Mar21) TTM:
Net Income was -6.144 + -8.668 + -6.971 + -33.409 = $-55.19 Mil.
Cash Flow from Operations was -7.984 + -6.315 + -5.831 + -8.54 = $-28.67 Mil.
Revenue was 0.188 + 0.252 + 0.087 + 0.132 = $0.66 Mil.
Gross Profit was -0.014 + -0.088 + -0.005 + 0.046 = $-0.06 Mil.
Average Total Assets from the begining of this year (Mar21)
to the end of this year (Mar22) was
(65.71 + 60.85 + 54.995 + 48.39 + 26.445) / 5 = $51.278 Mil.
Total Assets at the begining of this year (Mar21) was $65.71 Mil.
Long-Term Debt & Capital Lease Obligation was $2.66 Mil.
Total Current Assets was $15.63 Mil.
Total Current Liabilities was $9.73 Mil.
Net Income was -7.895 + -8.687 + -8.098 + -8.142 = $-32.82 Mil.

Revenue was 0 + 0 + 0.224 + 0.258 = $0.48 Mil.
Gross Profit was 0 + 0 + 0.053 + 0.096 = $0.15 Mil.
Average Total Assets from the begining of last year (Mar20)
to the end of last year (Mar21) was
(55.335 + 47.712 + 80.452 + 72.011 + 65.71) / 5 = $64.244 Mil.
Total Assets at the begining of last year (Mar20) was $55.34 Mil.
Long-Term Debt & Capital Lease Obligation was $7.93 Mil.
Total Current Assets was $28.47 Mil.
Total Current Liabilities was $14.41 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zosano Pharma's current Net Income (TTM) was -55.19. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zosano Pharma's current Cash Flow from Operations (TTM) was -28.67. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar21)
=-55.192/65.71
=-0.83993304

ROA (Last Year)=Net Income/Total Assets (Mar20)
=-32.822/55.335
=-0.59315081

Zosano Pharma's return on assets of this year was -0.83993304. Zosano Pharma's return on assets of last year was -0.59315081. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zosano Pharma's current Net Income (TTM) was -55.19. Zosano Pharma's current Cash Flow from Operations (TTM) was -28.67. ==> -28.67 > -55.19 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=2.662/51.278
=0.0519131

Gearing (Last Year: Mar21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar20 to Mar21
=7.934/64.244
=0.12349791

Zosano Pharma's gearing of this year was 0.0519131. Zosano Pharma's gearing of last year was 0.12349791. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar22)=Total Current Assets/Total Current Liabilities
=15.632/9.73
=1.6065776

Current Ratio (Last Year: Mar21)=Total Current Assets/Total Current Liabilities
=28.473/14.408
=1.97619378

Zosano Pharma's current ratio of this year was 1.6065776. Zosano Pharma's current ratio of last year was 1.97619378. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zosano Pharma's number of shares in issue this year was 4.248. Zosano Pharma's number of shares in issue last year was 2.981. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-0.061/0.659
=-0.09256449

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.149/0.482
=0.30912863

Zosano Pharma's gross margin of this year was -0.09256449. Zosano Pharma's gross margin of last year was 0.30912863. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar21)
=0.659/65.71
=0.01002891

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar20)
=0.482/55.335
=0.00871058

Zosano Pharma's asset turnover of this year was 0.01002891. Zosano Pharma's asset turnover of last year was 0.00871058. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+0+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zosano Pharma has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Zosano Pharma  (OTCPK:ZSANQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zosano Pharma Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Zosano Pharma's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zosano Pharma (Zosano Pharma) Business Description

Traded in Other Exchanges
N/A
Address
34790 Ardentech Court, Fremont, CA, USA, 94555
Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.
Executives
Christine Matthews officer: Chief Financial Officer C/O ZOSANO PHAMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Steven Lo director, officer: Chief Executive Officer C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94010
Donald J Kellerman officer: VP, Clinical Dev & Med Affairs INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Elaine Yang director C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Kenneth Greathouse director 3260 WHIPPIE ROAD, UNION CITY CA 94587
Hayley Lewis officer: See Remarks C/O CARBYLAN THERAPEUTICS, INC., 3181 PORTER DRIVE, PALO ALTO CA 94304
Kathy M. Mcgee director C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
Joseph P Hagan director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kleanthis G Xanthopoulos director 9050 CAMINO SANTA FE, SAN DIEGO CA 92121
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
Aisling Capital Partners Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iv Llc 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022